For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 68,607 | |||
| General and administrative | 24,724 | |||
| Total operating expenses | 93,331 | |||
| Loss from operations | -93,331 | |||
| Interest income | 2,682 | |||
| Other income, net | 52 | |||
| Total other income, net | 2,734 | |||
| Net loss before income tax expense | -90,597 | |||
| Net loss | -90,597 | |||
| Net unrealized (loss) gain on marketable securities | -28 | |||
| Comprehensive loss | -90,625 | |||
| Basic EPS | -0.59 | |||
| Diluted EPS | -0.59 | |||
| Basic Average Shares | 152,971,259 | |||
| Diluted Average Shares | 152,971,259 | |||
Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc. (TNYA)